LaFleur & Godfrey LLC Sells 697 Shares of Stryker Corporation $SYK

Key Points

• LaFleur & Godfrey LLC reduced its stake in Stryker Corporation by 0.9%, now holding 75,323 shares valued at approximately $29.8 million.
• Stryker's quarterly earnings exceeded expectations with $3.13 EPS and revenues of $6.02 billion, reflecting an 11.1% increase year-over-year.
• The company declared a quarterly dividend of $0.84 per share, representing an annualized yield of 0.9%, with a payout ratio of 44.5%.

LaFleur & Godfrey LLC lessened its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 0.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 75,323 shares of the medical technology company's stock after selling 697 shares during the period. Stryker comprises approximately 3.7% of LaFleur & Godfrey LLC's investment portfolio, making the stock its 4th biggest holding. LaFleur & Godfrey LLC's holdings in Stryker were worth $29,800,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Sunflower Bank N.A. raised its stake in Stryker by 4.0% in the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company's stock worth $275,000 after buying an additional 27 shares in the last quarter. Continuum Advisory LLC raised its stake in Stryker by 5.8% in the first quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company's stock worth $198,000 after buying an additional 29 shares in the last quarter. Oakworth Capital Inc. raised its stake in Stryker by 0.5% in the first quarter. Oakworth Capital Inc. now owns 6,133 shares of the medical technology company's stock worth $2,283,000 after buying an additional 29 shares in the last quarter. Strategy Asset Managers LLC raised its stake in Stryker by 1.4% in the first quarter. Strategy Asset Managers LLC now owns 2,134 shares of the medical technology company's stock worth $794,000 after buying an additional 29 shares in the last quarter. Finally, Tritonpoint Wealth LLC raised its stake in Stryker by 0.7% in the first quarter. Tritonpoint Wealth LLC now owns 4,042 shares of the medical technology company's stock worth $1,508,000 after buying an additional 30 shares in the last quarter. Institutional investors own 77.09% of the company's stock.

Stryker Trading Up 0.5%

Stryker stock traded up $1.87 during trading on Monday, hitting $378.70. The company had a trading volume of 2,095,205 shares, compared to its average volume of 985,669. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The company's 50 day simple moving average is $387.26 and its 200-day simple moving average is $379.05. The stock has a market cap of $144.78 billion, a price-to-earnings ratio of 50.16, a price-to-earnings-growth ratio of 2.71 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. During the same quarter last year, the company posted $2.81 EPS. The firm's revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's payout ratio is 44.50%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Wall Street Zen raised Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a report on Monday, July 14th. Truist Financial set a $415.00 price target on shares of Stryker and gave the company a "hold" rating in a report on Monday, August 4th. Needham & Company LLC increased their target price on shares of Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Finally, Evercore ISI raised their price target on shares of Stryker from $390.00 to $415.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Fourteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, Stryker has a consensus rating of "Moderate Buy" and an average price target of $430.33.

Insider Buying and Selling at Stryker

In other news, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company's stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.